KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Payables (2016 - 2025)

CRISPR Therapeutics AG's Payables history spans 11 years, with the latest figure at $11.1 million for Q4 2025.

  • For Q4 2025, Payables fell 24.28% year-over-year to $11.1 million; the TTM value through Dec 2025 reached $11.1 million, down 24.28%, while the annual FY2025 figure was $11.1 million, 24.28% down from the prior year.
  • Payables for Q4 2025 was $11.1 million at CRISPR Therapeutics AG, down from $11.8 million in the prior quarter.
  • Across five years, Payables topped out at $45.2 million in Q1 2023 and bottomed at $9.5 million in Q2 2024.
  • The 5-year median for Payables is $15.2 million (2021), against an average of $20.0 million.
  • The largest annual shift saw Payables soared 215.87% in 2022 before it tumbled 65.74% in 2024.
  • A 5-year view of Payables shows it stood at $14.8 million in 2021, then surged by 85.12% to $27.4 million in 2022, then surged by 39.08% to $38.1 million in 2023, then plummeted by 61.44% to $14.7 million in 2024, then dropped by 24.28% to $11.1 million in 2025.
  • Per Business Quant, the three most recent readings for CRSP's Payables are $11.1 million (Q4 2025), $11.8 million (Q3 2025), and $9.8 million (Q2 2025).